EXPERIENCE WITH THE USE OF PIOGLITAZONE FOR THE PREVENTION AND TREATMENT OF EXPERIMENTAL URATE NEPHROLITHIASIS

V. Y. Perfiliev, Y. F. Zverev, A. Y. Zharikov, D. Y. Lukiyanenko, I. V. Lysenko, O. S. Atabaeva
2017 Nephrology (Saint-Petersburg)  
THE AIM. To assess the effectiveness of selective agonist of PPAR gamma receptors (Peroxisome Proliferator-Activated Receptor) pioglitazone, as a drug of prevention and treatment of experimental urate nephropathy. MATERIAL AND METHODS. The study was conducted on 37 male rats Wistar stock. For the formation of urate nephropathy in rats inhibited uricase by co-administration of uric acid and oxonium. For the prevention and treatment of experimental pathology animals received pioglitazone. On day
more » ... oglitazone. On day 21 using biochemical and morphological techniques were evaluated received changes. RESULTS. In the experimental condition were observed significant decrease of urate stones in kidneys, significant decrease of uric acid in blood plasma and urine of rats, increase of the urine pH, increase of glomerular filtration rate and inhibition processes of free radical oxidation in the blood of animals. CONCLUSION. Long-term use of pioglitazone in the preventive and therapeutic modes, significantly improves the experimental urate nephrolithiasis.
doi:10.24884/1561-6274-2017-21-1-52-56 fatcat:ex4zupioxjfm3hadzzqm6rgsxq